Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Avid Bioservices Inc (CDMO)

Avid Bioservices Inc (CDMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,567,164
  • Shares Outstanding, K 61,098
  • Annual Sales, $ 95,870 K
  • Annual Income, $ 11,210 K
  • 60-Month Beta 2.21
  • Price/Sales 16.63
  • Price/Cash Flow 101.86
  • Price/Book 20.56
Trade CDMO with:

Options Overview

Details
  • Implied Volatility 63.00%
  • Historical Volatility 32.78%
  • IV Percentile 30%
  • IV Rank 22.21%
  • IV High 164.09% on 08/13/20
  • IV Low 34.15% on 05/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,542
  • Open Int (30-Day) 3,892

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/21
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year 0.06
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.20 +5.99%
on 07/19/21
27.02 -5.07%
on 07/02/21
unch (unch)
since 06/30/21
3-Month
18.54 +38.35%
on 05/11/21
27.02 -5.07%
on 07/02/21
+4.24 (+19.83%)
since 04/30/21
52-Week
6.61 +288.34%
on 09/08/20
27.02 -5.07%
on 07/02/21
+18.39 (+253.31%)
since 07/30/20

Most Recent Stories

More News
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing...

CDMOP : 25.06 (unch)
CDMO : 25.65 (-1.69%)
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million --

CDMOP : 25.06 (unch)
CDMO : 25.65 (-1.69%)
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing...

CDMOP : 25.06 (unch)
CDMO : 25.65 (-1.69%)
Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDMO : 25.65 (-1.69%)
Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?

Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

CDMO : 25.65 (-1.69%)
Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis

Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.

ILMN : 495.75 (+0.84%)
BMY : 67.87 (-0.41%)
CDMO : 25.65 (-1.69%)
AKRO : 21.44 (-0.92%)
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA(TM) (Loncastuximab Tesirine-Lpyl)

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development...

CDMO : 25.65 (-1.69%)
CDMOP : 25.06 (unch)
ADCT : 21.04 (-0.71%)
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

OMER : 14.50 (-1.96%)
ADPT : 36.66 (+0.14%)
ATNX : 3.77 (unch)
CDMO : 25.65 (-1.69%)
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

BMY : 67.87 (-0.41%)
AGIO : 48.09 (-3.51%)
NBRV : 1.1000 (-0.90%)
CDMO : 25.65 (-1.69%)
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

TEVA : 9.65 (-0.41%)
RDY : 62.55 (-1.17%)
AMRN : 4.14 (-2.36%)
CDMO : 25.65 (-1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing...

See More

Key Turning Points

3rd Resistance Point 27.07
2nd Resistance Point 26.76
1st Resistance Point 26.20
Last Price 25.65
1st Support Level 25.33
2nd Support Level 25.02
3rd Support Level 24.46

See More

52-Week High 27.02
Last Price 25.65
Fibonacci 61.8% 19.22
Fibonacci 50% 16.81
Fibonacci 38.2% 14.40
52-Week Low 6.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar